ULK1 and acute myeloid leukemia: Moreover, when AML-bearing mice were treated with MRT-68921, with a lower IC50 against its molecular target, ULK-1, than SBI-0206965, both total WBCs and leukemia cells were efficiently reduced in the PB (Fig. 6e, f) with an improved survival rate (Fig. 6g).